2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Melanoma
22
Sarcoma
8
Breast Neoplasms
5
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Carcinoma, Squamous Cell
3
Pancreatic Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Basal Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sezary Syndrome
1
Sarcoma, Kaposi
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Paget Disease, Extramammary
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Muir-Torre Syndrome
1
Microcystic adnexal carcinoma
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Interventions
Sorafenib
222
lenvatinib
147
Bevacizumab
131
Nivolumab
87
atezolizumab
81
pembrolizumab
74
Radiosurgery
71
durvalumab
63
sintilimab
61
Oxaliplatin
60
Fluorouracil
56
Doxorubicin
47
tislelizumab
46
apatinib
45
Radiofrequency Ablation
44
Hepatectomy
43
camrelizumab
41
Leucovorin
41
Radiotherapy
40
tremelimumab
37
Magnetic Resonance Spectroscopy
36
regorafenib
34
Capecitabine
30
Immune Checkpoint Inhibitors
29
Folfox protocol
29
Cisplatin
28
cabozantinib
26
Gemcitabine
26
Cyclophosphamide
26
Ipilimumab
25
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
talimogene laherparepvec
×
Clear all
NCT02509507
2024-08-06
MASTERKEY-318
Amgen
Phase 1/2
Completed
127 enrolled
37 charts